The Companion Series
About us
We’re an independent publisher of plain-English health education — built on a simple observation: millions of people are now taking a category of medication that almost nobody explained to them properly.
What we make
The Companion Series creates structured, self-paced educational guides — starting with The 90-Day Companion, which explains life on a GLP-1 receptor agonist one topic at a time, in language that respects your intelligence and your schedule. Every guide ships with practical tools: a weekly body log, a prescriber playbook, and a protein and strength primer. Because understanding is only half the job. The other half is walking into an appointment with organized evidence.
How we work
Everything we publish is grounded in citable sources: FDA prescribing information, the peer-reviewed trial literature, and the 2025 joint nutrition advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Where the evidence is strong, we say so. Where it’s young or uncomfortable — what happens when people stop, what happens to muscle — we say that too, plainly, including the parts that make for a worse sales page. That honesty is the product.
What we don’t do
We are educators, not clinicians. Our materials never diagnose, prescribe, or replace medical care. We publish no dosing guidance of any kind — not doses, not schedules, not titration, not tapering, and nothing about “microdosing.” Those decisions depend on a history a PDF cannot know, and they belong to the person who wrote your prescription.
Who pays us
You do, and only you. We are not affiliated with any pharmaceutical company. We sell no medications and provide no prescriptions. We accept no funding, sponsorship, affiliate commission, or advertising from drug manufacturers, telehealth services, compounding pharmacies, or supplement brands, and we recommend no products.
We say this prominently because this audience has been marketed to relentlessly by companies with something to sell, and because it’s the reason we can afford to include a chapter on what happens when you stop taking the medication.